Sign In
Buy XAIR
$0.442
-0.0282 (-6.00%)
At Close: Jun 03, 2026
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
08:00am, Monday, 01'st Jun 2026
GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (N
Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026
08:00am, Monday, 20'th Apr 2026
Updated AACR poster data show continued survival follow-up in heavily pre ‑ treated patients following a single intratumoral UNO injection
Beyond Air to Participate in the D. Boral Capital Global Conference 2026
08:00am, Wednesday, 15'th Apr 2026
GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (
Beyond Air, Inc. (NASDAQ:XAIR) Short Interest Update
02:39am, Sunday, 29'th Mar 2026
Beyond Air, Inc. (NASDAQ: XAIR - Get Free Report) was the target of a large drop in short interest in the month of March. As of March 13th, there was short interest totaling 114,054 shares, a drop of
Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial
04:35pm, Tuesday, 17'th Mar 2026
Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19th Data was published in the Online Itinerary Planner fo
GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on
Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript
10:37am, Friday, 13'th Feb 2026
Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
07:30am, Friday, 13'th Feb 2026
Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
04:05pm, Tuesday, 27'th Jan 2026
GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on
Beyond Air, Inc. (NASDAQ:XAIR) Short Interest Update
02:20am, Monday, 19'th Jan 2026
Beyond Air, Inc. (NASDAQ: XAIR - Get Free Report) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totaling 237,064 shares, a decrease of
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease
Beyond Air, Inc. (NASDAQ:XAIR) Sees Significant Decline in Short Interest
02:13am, Tuesday, 30'th Dec 2025
Beyond Air, Inc. (NASDAQ: XAIR - Get Free Report) saw a significant decline in short interest in December. As of December 15th, there was short interest totaling 292,952 shares, a decline of 20.6% fro
Contrasting Beyond Air (NASDAQ:XAIR) & Cartesian Therapeutics (NASDAQ:RNAC)
03:16am, Thursday, 25'th Dec 2025
Beyond Air (NASDAQ: XAIR - Get Free Report) and Cartesian Therapeutics (NASDAQ: RNAC - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the
Chagee Holdings, Tilray Brands And 3 Stocks To Watch Heading Into Friday
12:57am, Friday, 28'th Nov 2025
US stock futures higher. Chagee Holdings, Tilray Brands, Globus Maritime, Post Holdings, and Beyond Air in focus.
Beyond Air® Announces Transition of Chief Financial Officer
04:30pm, Wednesday, 26'th Nov 2025
GARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on
